Rompoti N, et al. - According to Physician Global Assessment (PGA), PASI75/90/100 and scalp and palmoplantar PGA, researchers conducted this single-center clinical study to assess in real-world practice the effectiveness of secukinumab up to week 104 of treatment in moderate-to-severe chronic plaque psoriasis, including the scalp and palmoplantar involvement. During a 2-year observation period, drug survival, the safety profile of secukinumab and patient's quality of life were also evaluated. Of the 83 patients included, 56.3% were biologic-naïve and 94% had scalp, 25.3% palmoplantar and 43.9% joint involvement. There has been a substantial improvement in the quality of life. The most benefited were biologic-naïve patients without coexisting psoriatic arthritis. Real-world data showed secukinumab efficacious in chronic plaque psoriasis, including specific locations like the scalp and palmoplantar psoriasis with a safety profile comparable to that in clinical trials.